{"ModuleTitle": "Company Description", "CompanyName": "Spectrum Pharmaceuticals, Inc.", "Symbol": "SPPI", "Address": "11500 S. EASTERN AVE., SUITE 240, HENDERSON, Nevada, 89052, United States of America", "Phone": "702-835-6300", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Spectrum Pharmaceuticals, Inc. (\"Spectrum\", the \"Company\", \"we\", \"our\", or \"us\")\r\nis a biopharma company, with a primary strategy comprised of acquiring,\r\ndeveloping, and commercializing novel and targeted oncology therapies. Our\r\nin-house development organization includes clinical development, regulatory,\r\nquality and data management. We plan to build out our commercial and marketing\r\ncapabilities in the second half of 2020 to prepare for the launch of ROLONTIS.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f02%2f0000831547-20-000009.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Francois Lebel", "title": "Chief Medical Officer"}, {"name": "Joseph W. Turgeon", "title": "President, Chief Executive Officer & Director"}, {"name": "Kurt A. Gustafson", "title": "Chief Financial Officer & Executive Vice President"}, {"name": "Lyndah K. Dreiling", "title": "Senior Vice President-Clinical Development"}, {"name": "Thomas J. Riga", "title": "Executive VP, Chief Operating & Commercial Officer"}], "Number_of_employees": [], "Subsidiaries": ["NO INFO"]}